menu
    • menu
    [{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Metopimazine Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurogastrx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neurogastrx \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Metopimazine Mesylate

    Menu

    Metopimazine Mesylate

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurogastrx

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Neurogastrx

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metopimazine Mesylate,Semaglutide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurogastrx Shows Positive Data for NG101 in GLP-1 Related Nausea

                            Details : NG101 is an oral, peripherally restricted dopamine D2 receptor antagonist, being investigated for nausea and vomiting side effects caused by GLP-1 agonist medication.

                            Brand Name : NG101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : Metopimazine Mesylate,Semaglutide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurogastrx

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Neurogastrx

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metopimazine Mesylate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Vivo Capital

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Neurogastrx Secures $60 Million Series B Financing to Advance Gastrointestinal Therapies

                            Details : Company will use the proceeds to advance its GI therapies including fexuprazan for the treatment of erosive esophagitis and NG101 (metopimazine mesylate) for gastroparesis.

                            Brand Name : NG101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 26, 2021

                            Lead Product(s) : Metopimazine Mesylate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Vivo Capital

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth